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A B S T R A C T   
Associated with their roles as targets for tumour promoters, there has been a long-standing in-
terest in how members of the protein kinase C (PKC) family act to modulate cell growth and 
division. This has generated a great deal of observational data, but has for the most part not 
afforded clear mechanistic insights into the control mechanisms at play. Here, we review the roles 
of PKCε in protecting transformed cells from non-disjunction. In this particular cell cycle context, 
there is a growing understanding of the pathways involved, affording biomarker and interven-
tional insights and opportunities.   
1. Introduction 
Taking a highly reductionist perspective on cellular controls, the mammalian cell cycle can be broken down into three types of 
regulatory input. The first being the ‘decision’ to divide, reflecting a dominance of growth promoting signals over inhibitory signals 
sustained through to the G1 restriction point, i.e. the point of no return with respect to cell cycle commitment (reviewed (Fisher, 
2016)). In multicellular organisms, this entry into cycle is determined to a significant extent by the external environment (cell--
cell/matrix contact, hormones/growth factors, nutrients, etc), leading to the accumulation of active CyclinD/Cdk4/6 activity, the 
phosphorylation of pocket proteins and the activation of E2F (reviewed (Cobrinik, 2005)), which in turn elicits the accumulation of 
active CyclinE/Cdk2. The second class of regulatory input relates to the timing and process of division (one cycle at a time, complete 
and proof-read replication, sister chromatid disjunction, etc); these controls are cell autonomous, imposed on the underlying ma-
chinery delivering division (DNA polymerases, microtubule motor driven chromosome separation, etc) and largely concern the 
integrity of the division itself. These autonomous properties are exquisitely exemplified by the process of origin licensing which re-
stricts origin firing to once and only once per cell cycle (reviewed (Marks et al., 2017)). Thirdly, there are the controls imposing 
protective responses to pathological, internal/external challenges (DNA damage, replication stress, etc; see recent reviews(Blackford 
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and Stucki, 2020; Ovejero et al., 2020)) impacting the progression of the division process and eliciting decisions to either delay 
progression, resolve problems and complete division, or abort and take an organism protective cell cycle exit strategy e.g. senescence, 
or apoptosis (Krenning et al., 2019; Petr et al., 2020). 
The majority of literature relating to PKC isoforms and cell cycle controls concerns entry into cycle, i.e. the G0-G1 transition 
through to the restriction point, and there are clearly model dependent pro- and anti-proliferative behaviours for individual isoforms 
creating a complicated picture (reviewed (Black and Black, 2012; Poli et al., 2014)). Notwithstanding work in these ex vivo models, a 
lack of an absolute requirement for PKC family genes for cell division in vivo in the mouse (all knockouts are viable excepting PKCι and 
PKN2), suggests that for the controls operating to progress a ‘normal’ cell cycle, these proteins are not required. Furthermore, in the 
case of PKCι, conditional knockout in the adult does not prevent the transformation of AT2 cells in the lung by mutant Ras (Yin et al., 
2019), consistent with the lack of any fundamental requirement in the cell cycle. A similar argument can be made for PKN2 where the 
knockout appears to display selective defects in mesenchymal tissue (Quetier et al., 2016). 
With respect to the third class of regulatory inputs to the cell cycle, there are examples of PKC isoforms acting in response to stress 
and contributing to cell cycle arrest, e.g. the action of PKCδ contributing the DNA damage checkpoint (LaGory et al., 2010) and 
damage-associated apoptosis (Basu, 2003). There is limited mechanistic insight into how these PKC isoform requirements act or the 
nature of the proximal targets engaged. However, in the case of PKCε recent evidence has created the foundations of a deeper un-
derstanding of its engagement in a particular cell cycle setting and discussion of these processes is the focus of this review. The 
properties of PKCε and functions previously ascribed to this isoform in the context of cell cycle/proliferation are discussed briefly by 
way of background, before detailing the operation of the protective, PKCε-dependent cell cycle programme. 
Fig. 1. Organisation of PKCε. A schematic diagram is shown of the domains of PKCε from the N-terminus (top) through the C2 domain, pseu-
dosubstrate site (PSS), C1A domain, inter C1 domain region (IC1D), C1B domain, variable 3 region (V3) and C-terminal Kinase domain (Kin). 
Interacting ligands germane to the review are indicated; specifically, diacylglycerol (DAG) in a membrane compartment, 14-3-3, autoinhibition with 
the PSS binding the kinase domain substrate site (——). Post-translational events discussed in the text are illustrated alongside their effectors 
(kinases/target sites and protease/cleavage sites). Canonical and non-canonical activation pathways are indicated and colour coded. (For inter-
pretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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1.1. PKCε properties 
The PKCε isoform retains many of the basic properties shared with other members of this serine/threonine protein kinase family 
(see reviews (Mellor and Parker, 1998; Zeng et al., 2012)). The protein is organised in a modular fashion with an N-terminal regulatory 
domain comprising a Ca2+-insensitive C2 domain, an inhibitory pseudosubstrate site, two C1 domains (C1A and C1B) with a short 
intervening sequence (inter C1 domain, IC1D), followed by a V3 region that links to the C-terminal kinase domain (Fig. 1). In most cells 
and tissues in the basal state, PKCε is in a closed autoinhibited conformation, with the inhibitory pseudosubstrate site occupying the 
kinase domain substrate binding pocket. The conformation of the kinase domain that engages the autoinhibitory site is typically 
phosphorylated on three priming sites in the activation loop (PDK1 dependent (Dutil et al., 1998; Le Good et al., 1998);) and at the turn 
motif and at the hydrophobic motif at the C-terminus (both mTORC2-dependent (Cameron et al., 2011)) This closed and phosphor-
ylated conformer, is thus inactive through steric autoinhibition, but nevertheless is in a latent active state such that on ligand/partner 
binding, which triggers an open conformation, activity of the kinase is expressed without the demand of upstream kinase action. This 
contrasts starkly with the related AGC protein kinases of the Akt family, which require acute phosphorylation by PDK1/mTORC2 for 
activity (see (Cameron et al., 2007)). 
Canonical, ligand dependent activation of PKCε involves the ‘breathing’ of the regulatory domain-catalytic domain inhibitory 
interaction, such that the C1 domains can ‘sample’ membrane compartment(s) and bind their endogenous ligand diacylglycerol (DAG). 
The extent to which this opening of the conformation is influenced by for example C2 domain binding to proteins/membranes is not 
established. For PKCβ a role for the C2 domain driven by Ca2+ has been established (Nalefski and Newton, 2001). This canonical 
activation of PKCε is likely associated with various receptor triggered phospholipase C-dependent responses (Bunney and Katan, 2011) 
and pharmacologically triggered by C1-binding phorbol esters and related agents (Kazanietz, 2002). These pharmacological agents 
have a sustained effect on their targets as unlike DAG, they are not rapidly metabolised. Prolonged activation triggered in this manner 
has demonstrated that in their active states PKC family members are typically downregulated and this is in part associated with 
dephosphorylation and degradation (see (Newton, 2010)). 
There are at least two ‘non-canonical’ pathways to activation that are pertinent to this review. The first relates to the original 
pioneering discovery of PKC by Nishizuka and colleagues, where it was shown that proteolysis was responsible for revealing activity in 
crude extracts (Takai et al., 1977). While these observations almost certainly related to the cPKC isoforms (α, β γ), it has been shown 
that purified PKCε can also be activated by proteolysis through cleavage in its V3 domain (Schaap et al., 1990), by inference reducing 
the engagement of the autoinhibitory regulatory domain and the kinase domain (Fig. 1). It has been shown that physiologically, 
caspase activation can also drive V3 domain cleavage (Basu et al., 2002) and this turns out to be central to an M-Phase engagement of 
PKCε (see further below (Kelly et al., 2020)). A second non-canonical activation pathway for PKCε involves the assembly of a 
PKCε-14-3-3 complex (Saurin et al., 2008). The 14-3-3 family of scaffolding proteins function as obligate dimers to interact with and 
control partner proteins in a highly regulated fashion, typically but not exclusively through recognition of site-specific phosphorylation 
(Obsilova et al., 2014). In the PKCε complex, interaction is with two distinct sites in the V3 domain (Kostelecky et al., 2009) that are 
phosphorylated through the action of p38 at Ser350 priming GSK3 to target the proximal Ser346 site and also an autophosphor-
ylation/AGC kinase phosphorylation at Ser368 (Saurin et al., 2008) (see Fig. 1). Assembly of this complex appears to open the 
conformation of PKCε eliciting a lipid-independent activity (Saurin et al., 2008). It is notable that for both of these non-canonical 
mechanisms, the activated form of PKCε has the capacity to engage targets that are not necessarily constrained at the membrane. 
1.2. PKCε suppressive and proliferative actions 
Early studies associated with the ectopic expression of PKCε in adherent mesenchymal cells (NIH3T3, Rat6 cells), provided evi-
dence that PKCε was ‘oncogenic’, in conferring an increased growth rate, growth to a higher density and growth in soft agar (Cacace 
et al., 1993; Mischak et al., 1993). This was associated in Rat6 cells with altered cyclin expression (Han et al., 1995). The effects in 
NIH3T3 cells were shown to be kinase domain dependent based upon the use of δ/ε chimera expression in a xenograft setting (Wang 
et al., 1998). In the LNCaP prostate cell model, ectopic PKCε was shown to trigger androgen-independent proliferation again impacting 
ERK activation and translation of 5′-cap-dependent mRNAs (Wu et al., 2002). In the LM3 breast cell model, PKCε expression also 
promotes anchorage independent growth and is pro-metastatic (Grossoni et al., 2009). In the GH3B6 pituitary tumour cell line, 
PMA-induced proliferation has been shown to be associated with PKCα and ε activation correlating with activation of ERK pathways 
(Petiti et al., 2010), although it is noted that all isoforms have the capacity to trigger ERK pathway activation (Schonwasser et al., 
1998). Consistent with a growth promoting behaviour, miRNA-146a is a reported tumour suppressor and has been found to bind to 
PKCε mRNA and reduce protein expression associated with inhibition of proliferation in a papillary thyroid carcinoma model (Zhang 
et al., 2014). Down-regulation of PKCε protein by phorbol esters can also impact proliferation through loss of protective mechanisms as 
observed in primary AML cells and their sensitisation to TRAIL induced apoptosis (Gobbi et al., 2009). 
In mouse models, there is evidence of cancer promotion activity associated with ectopic PKCε expression. Overexpression of PKCε 
in the epidermis sensitises to PMA-induced carcinoma formation effectively by-passing the papilloma stage (Reddig et al., 2000). 
Probasin promoter-driven expression of PKCε in the mouse prostate elicits a typical preneoplastic prostate lesion (Benavides et al., 
2011). In this model, the additional deletion of PTEN synergises in tumour formation, acting through a CXCL13/CXCR5 autocrine 
mechanism (Garg et al., 2017). 
Interestingly, inhibition of proliferation and cell cycle arrest associated with PKCε action has been reported in a number of contexts, 
in part linked to cell cycle inhibition associated with late G1 treatment with low doses of the tumour promoter PMA (Huang and Ives, 
1987). In lymphoblastoid cells, this inhibition of proliferation in response to low dose PMA, was shown to be sensitised by ectopic 
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expression of PKCε (Mihalik et al., 1996). A similar effect was observed in rat 3Y1 cells, although PKCα, δ and ε all sensitised to PMA in 
this setting acting through inhibition of E2F (Nakaigawa et al., 1996). Low density NIH3T3 cells are also sensitive to PMA-induced 
inhibition of cell cycle progression and here it has been reported that PKCε mediates this effect through induction of the Cdk inhib-
itor p21 (Petrovics et al., 2002). Contrary effects on p21 have been reported in non-small cell lung cancer lines based on the use of 
siRNA and dominant negative kinase dead PKCε approaches (Bae et al., 2007), although it is noted that the mutational manipulation 
associated with mutations in the conserved lysine can have pleiotropic effects (Garcia-Paramio et al., 1998). Interestingly the inhi-
bition of proliferation through PKCε has been observed also in normal haematopoiesis (Bassini et al., 1999; Gobbi et al., 2013) and in 
restoring differentiation of hematopoietic progenitors from primary myelofibrosis patients (Masselli et al., 2015). 
These studies illustrate the extremes relating to PKCε in terms of cell cycle controls, proliferation and transformation. It is likely that 
the variations in behaviour reflect a combination of the high level of expression of the ectopic protein, with the potential for non- 
specific effects on cell cycle behaviour (acknowledging that such variations can occur in pathological settings), and the cell-specific 
wiring of cell cycle controls in divergent models under different growth conditions. Whilst expression changes in PKCε have been 
described in cancer transcriptomic studies, evidence that any of these effects plays out functionally in cancer patients is missing and 
this is reflective of a paucity of mechanistic insight into specific PKCε actions for which biomarkers might then inform on its action in 
disease states. 
1.3. A PKCε dependent genome protective programme 
In a subset of transformed cell models, three points of dependence on PKCε have been described that serve to delay cell cycle 
progression and protect from sister chromatid non-disjunction (Fig. 2). The common property defining dependence on PKCε for all 
three actions and prompting the notion of an alternative regulatory programme, is the inability to execute a Topoisomerase2(Topo2)- 
dependent G2 arrest apparent on treatment with the Topo2 inhibitor ICRF193 (note this is not a Topo2 poison). This arrest has been 
referred to as a G2 checkpoint (Downes et al., 1994), however it is perhaps more accurately described as a Topo2A dependent G2 
arrest. The implementation of this arrest is dependent upon a set of genes that are distinguished from those engaged in DNA damage 
responses and involves inter alia the action of the SMC5/6 complex triggering SUMOylation of Topo2A at a C-terminal site (Deiss et al., 
2019). Loss of SMC5/6 or associated subunits, or in the case of a rare patient mutation, inactivation of the NSE2 subunit, prevents the 
Fig. 2. PKCε action in transformed cells. The Topo2-dependent arrest in G2 is indicated diagrammatically in the context of a normal cell cycle. The 
switch to a PKCε-dependent pathway (red) occurs in cells failing to arrest (see text). This leads to a series of delays under the control of PKCε as 
indicated. These are implemented by distinct mechanisms (see text for a more detailed discussion). Resolution of non-disjunction stress enables the 
maintenance of chromosomal integrity and the completion of division; failure to resolve produces division failure and/or chromosome damage. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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normal G2 arrest on ICRF193 treatment (Deiss et al., 2019). 
Associated with dysfunction of this arrest pathway in transformed cells, is a characteristic progression through cycle despite 
retention of non-disjoined, catenated sister chromatids, problems exacerbated by the additional loss of PKCε activity (Brownlow et al., 
2014). The sensing mechanisms have yet to be defined, but the engagement and requirement for PKCε are interpreted as supporting 
protective actions in delaying cell cycle progression, to effect resolution from non-disjunction and hence the successful completion of 
cell division. 
1.4. The aurora B abscission checkpoint 
The initial evidence relating to the action of PKCε in this checkpoint arose from the finding that PKCε was phosphorylated in a cell 
cycle dependent manner at Ser346 (Saurin et al., 2008). This was found to be part of a series of V3 domain phosphorylations involved 
in the assembly of a 14-3-3 complex, a structure later resolved (Kostelecky et al., 2009) and a complex which was shown to be required 
for the efficient completion of cytokinesis in HeLa cells (Saurin et al., 2008). Subsequent evidence demonstrated that PKCε acted at 
cytokinesis to enable exit from the well characterised Aurora B abscission checkpoint (Pike et al., 2016). 
The abscission checkpoint is typically engaged when there is DNA sensed in the cleavage furrow (recently reviewed (Petsalaki and 
Zachos, 2019); (Nähse et al., 2017)). This checkpoint is dependent on Aurora B activity for its implementation and inhibition of Aurora 
B prior to arrest prevents checkpoint engagement and leads to completion of daughter cell separation associated with extensive DNA 
damage; inhibition post-implementation of the checkpoint, leads to furrow regression and failure to divide, indicating that Aurora B 
activity is required also for efficient exit from the checkpoint (Steigemann et al., 2009). PKCε appears to act in this second phase of 
Aurora B action and does so through the direct phosphorylation of Aurora B on Ser227 in the activation loop of the kinase (Pike et al., 
2016). Intriguingly this switches the substrate recognition behaviour of Aurora B such that it now has a much greater propensity to 
phosphorylate Borealin at Ser165; elimination of this phosphorylation on Borealin phenocopies PKCε inhibition providing strong 
evidence that this lies on the pathway of checkpoint exit (Pike et al., 2016). 
Aurora B is the catalytic component of the chromosome passenger complex (CPC) alongside the adaptor proteins INCENP, Borealin 
and Survivin (reviewed (Kitagawa and Lee, 2015)). Abscission checkpoint engagement involves Aurora B phosphorylation of CHMP4C 
at Ser210 (Carlton et al., 2012); Borealin in turn can interact with the ESCRTIII machinery protein CHMP4C (Capalbo et al., 2016). The 
checkpoint-associated delay to completion of cytokinesis appears to reflect the cooperation of CHMP4C with ANCHR in the seques-
tration of Vps4, which is required for completion of abscission at the abscission zone (Thoresen et al., 2014). It has been suggested that 
the inactivation of Aurora B is involved in the release of Vps4, however based upon the requirement for PKCε acting via Aurora B and 
Borealin it is likely that it is this switch in Aurora B activity that is involved in the release of Vps4, although this has not been 
established. Recent evidence indicates that the PP1 dependent dephosphorylation of CHMP4C S210 counteracts Aurora B action at this 
site, enabling checkpoint exit once DNA bridging has been resolved (Bhowmick et al., 2019). 
The requirement for 14-3-3 complex formation is clear in this process and this has been interpreted in respect of the lipid- 
independent activity associated with the assembly of this complex (as discussed above). This imples that the action of PKCε at the 
midbody may be independent of its membrane recruitment. This has yet to be resolved as indeed has the requirement of 14-3-3 for the 
midbody phosphorylation of Aurora B at Ser227; does this complex sit on the defined Aurora B phosphorylation pathway reflecting a 
necessary and sufficient output controlling abscission, or are there multiple parallel required outputs that have yet to be uncovered? 
1.5. Delayed SAC silencing 
The increase in anaphase irregularities associated with PKCε loss of function in ICRF193 non-arresting transformed cells (e.g. the 
higher frequency of PICH positive ultrafine bridges), indicated that even prior to its engagement in the abscission checkpoint, there 
was an exacerbation of underlying problems when PKCε is inhibited or knocked-down. This led to the observation that in such cells, 
PKCε controlled the timing of SAC silencing, delaying this by many tens of minutes and correlating with an increase in catenated sister 
chromatids in metaphase (Brownlow et al., 2014). This delay in anaphase entry is associated with the retention of BubR1 at kinet-
ochores, affording a transient BubR1high/Mad2low kinetochore biomarker of the imposed delay. The retention of BubR1 may in part 
explain the delay, given its role in the control of APC/C and hence onset of anaphase (see (Kapanidou et al., 2015)). 
More recently the mechanism of PKCε engagement in this process has been addressed and this is of particular interest given the 
chromatin-associated changes involved in the SAC silencing delay and the conventional activation of PKCε in membrane compart-
ments (see above). Notably in the context of this compartmental issue, it has been reported that there is a constitutive cell cycle 
dependent activation of PKCε in a chromatin sub-compartment that is effected by V3 domain cleavage (Kelly et al., 2020). Proteolysis 
occurs principally through Caspase 7 acting at Asp383 (the critical, activating V3 domain site) and Asp451 (kinase domain site), in line 
with earlier caspase site mapping work (Basu et al., 2002). This non-apoptotic caspase action is absolutely required for the delay to 
anaphase entry and mutation of the PKCε Asp383 caspase cleavage site blocks any delay to anaphase onset in a manner that is arti-
ficially reversible through regulated cleavage of an engineered TEV site or via expression of the kinase domain of PKCε but not the full 
length non-cleavable protein (Kelly et al., 2020). 
The kinase domain generated in this membrane-independent M-phase process triggers downstream events that act to promote 
resolution of chromatin catenation, based on the extent of retained sister chromatid catenation, and also to impose the delay to 
checkpoint silencing, as determined by the timing of anaphase entry (Kelly et al., 2020). Interestingly, an essential element in the 
actions of PKCε is again the phosphorylation of Aurora B at Ser277 (as at cytokinesis; see above) and in this context it was shown that 
this is critical to the activation of Topo2A through a switch in Aurora B phosphorylation of Topo2A (Kelly et al., 2020). There are 
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however other targets that are necessary for this arrest/resolution function based upon a genetic code expansion-based substrate 
screen and knock-down (Davis, Martini and Parker unpublished). How these additional candidate targets play into this delay in 
anaphase entry and non-disjunction resolution remains to be determined. 
1.6. Altered centrosome migration 
Investigation of pre-mitotic events that might reflect the engagement of this programme of PKCε dependency led to the observation 
that PKCε inhibition or loss influences the progress of centrosome separation, impacting mitotic spindle assembly (Martini et al., 
2018). It has yet to be determined what the activating triggers are for PKCε at this cell cycle stage, however it appears that the actions 
of PKCε are directed at cytoplasmic dynein. Thus in a cell cycle dependent manner, PKCε and dynein are found to interact as judged by 
co-immunoprecipitation and in situ proximity ligation assays (Martini et al., 2018). That these events are part of the PKCε protective 
programme is evident from centrosome migration being under PKCε control if and only if the G2 arrest is dysfunctional. 
1.7. PKCε, an opportunity for intervention? 
The requirement for PKCε to facilitate the efficient division of that subset of tumour cells with a defective Topo2-dependent G2 
arrest as observed on treatment with ICRF193, suggests that this very druggable protein is a rational target in this subset of cancer 
settings. The potential impact is high given the prevalence of this loss in tumour cell lines (~60%). Furthermore, the finding that the 
knockout of the gene in the mouse is viable, promises a good therapeutic index and although there may be some emergent de-
pendencies (e.g. in cardiac protection to ischemic events) this should be manageable in the context of a life-threatening cancer. 
The exacerbating effects of ICRF193 treatment in the context of PKCε inhibition in these sensitive models begs the question of 
whether significant benefit might only be seen when Topo2A is inhibited. This should be a tractable question in vivo through use of the 
structurally related inhibitor dexrazoxane which is deployed clinically as a cardio-protective agent in anthracycline treatment (see 
(Cvetković and Scott, 2005)). Whether the ex vivo behaviour of these models plays out in an in vivo setting and indeed whether this 
converts into a clinical opportunity remains to be determined. 
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